Bristol-Myers: Opdivo fails in phase III trial
(CercleFinance.com) - Bristol-Myers Squibb announces that its Phase III CheckMate -548 trial evaluating the addition of its Opdivo to the current standard of care has not achieved one of its primary endpoints in patients with a certain type of glioblastoma multiform.
The combination did not show a statistically significant improvement in progression-free survival. However, the monitoring committee recommends a continuation of the study, to evaluate the other main objective, i.e. overall survival.
As the most common and aggressive type of primary malignancy of the central nervous system, glioblastoma multiform affects less than 10 out of 100,000 people. The five-year survival rate for patients is below 5%.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The combination did not show a statistically significant improvement in progression-free survival. However, the monitoring committee recommends a continuation of the study, to evaluate the other main objective, i.e. overall survival.
As the most common and aggressive type of primary malignancy of the central nervous system, glioblastoma multiform affects less than 10 out of 100,000 people. The five-year survival rate for patients is below 5%.
Copyright (c) 2019 CercleFinance.com. All rights reserved.